HER2-targeted DEP antibody drug conjugate - Starpharma
Alternative Names: HER2 targeted DEP SN 38 antibody drug conjugateLatest Information Update: 14 Aug 2024
At a glance
- Originator Starpharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 14 Aug 2024 Preclinical development in Ovarian cancer (unspecified route) is still ongoing in Australia (Starpharma pipeline, August 2024)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in Australia (IV)
- 26 Apr 2023 Pharmacodynamics data from a preclinical study in Ovarian cancer released by Starpharma